New research shows promise for treating hepatitis C in pregnancy
Researchers and clinicians at WashU Medicine are helping reshape how hepatitis C virus (HCV) is treated during pregnancy, with a new study showing that a commonly used antiviral regimen can be used safely and effectively in pregnant patients in real-world care.
Researchers from WashU Medicine have found promising results for treating hepatitis C virus (HCV) in pregnant patients. The study, led by Dr. Laura Marks and Dr. Madeline McCrary, examined the use of the oral antiviral regimen glecaprevir-pibrentasvir in 14 pregnant patients between 14 and 32 weeks of gestation. Of these patients, 10 successfully completed the treatment, and all 10 achieved a virologic response by the time of delivery or earlier.
There were no reported maternal or neonatal safety concerns, indicating that the treatment may be feasible and safe in pregnancy. This study fills an important gap, as there had been no clinical trial data or real-world experience published for glecaprevir-pibrentasvir treatment in pregnancy until now. The findings were published in Clinical Infectious Diseases on August 11, 2026.
Dr. McCrary noted that the work is part of a larger effort to improve care for pregnant patients with HCV in the region, and the collaboration aims to build a new model of care for HCV in pregnancy that spans medication research, implementation science, and health economics.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
